- Home
- FEMY vs TPST Comparison
FEMY vs TPST Comparison
Compare FEMY & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- TPST
- Stock Information
- Founded
- FEMY 2004
- TPST 2011
- Country
- FEMY United States
- TPST United States
- Employees
- FEMY N/A
- TPST N/A
- Industry
- FEMY Medical/Dental Instruments
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- FEMY Health Care
- TPST Health Care
- Exchange
- FEMY Nasdaq
- TPST Nasdaq
- Market Cap
- FEMY 31.9M
- TPST 33.0M
- IPO Year
- FEMY 2021
- TPST N/A
- Fundamental
- Price
- FEMY $0.95
- TPST $6.92
- Analyst Decision
- FEMY Strong Buy
- TPST Hold
- Analyst Count
- FEMY 3
- TPST 3
- Target Price
- FEMY $8.67
- TPST $30.00
- AVG Volume (30 Days)
- FEMY 262.9K
- TPST 86.6K
- Earning Date
- FEMY 08-07-2025
- TPST 08-07-2025
- Dividend Yield
- FEMY N/A
- TPST N/A
- EPS Growth
- FEMY N/A
- TPST N/A
- EPS
- FEMY N/A
- TPST N/A
- Revenue
- FEMY $1,699,232.00
- TPST N/A
- Revenue This Year
- FEMY $231.84
- TPST N/A
- Revenue Next Year
- FEMY $245.28
- TPST N/A
- P/E Ratio
- FEMY N/A
- TPST N/A
- Revenue Growth
- FEMY 61.97
- TPST N/A
- 52 Week Low
- FEMY $0.69
- TPST $5.35
- 52 Week High
- FEMY $1.80
- TPST $30.03
- Technical
- Relative Strength Index (RSI)
- FEMY 46.82
- TPST 46.64
- Support Level
- FEMY $0.90
- TPST $7.06
- Resistance Level
- FEMY $0.99
- TPST $7.64
- Average True Range (ATR)
- FEMY 0.06
- TPST 0.26
- MACD
- FEMY 0.00
- TPST 0.00
- Stochastic Oscillator
- FEMY 18.18
- TPST 22.10
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.